Literature DB >> 21160759

Long term combination treatment for severe idiopathic pulmonary arterial hypertension.

Flora Affuso1, Plinio Cirillo, Antonio Ruvolo, Guido Carlomagno, Serafino Fazio.   

Abstract

We report the long-term follow-up of 3 cases of severe idiopathic pulmonary arterial hypertension, in whom tadalafil plus sitaxentan combination therapy improved the clinical condition and exercise performance without any relevant adverse event.

Entities:  

Keywords:  Endothelin receptors; Pulmonary hypertension; Sitaxentan; Tadalafil

Year:  2010        PMID： 21160759      PMCID： PMC2999023          DOI： 10.4330/wjc.v2.i3.68

Source DB:  PubMed          Journal:  World J Cardiol


  8 in total

1.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Authors:  Robyn J Barst; David Langleben; David Badesch; Adaani Frost; E Clinton Lawrence; Shelley Shapiro; Robert Naeije; Nazzareno Galie
Journal:  J Am Coll Cardiol       Date:  2006-04-24       Impact factor: 24.094

Review 2.  End points and clinical trial design in pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; David B Badesch; Marion Delcroix; Thomas R Fleming; Sean P Gaine; Nazzareno Galiè; J Simon R Gibbs; Nick H Kim; Ronald J Oudiz; Andrew Peacock; Steeve Provencher; Olivier Sitbon; Victor F Tapson; Werner Seeger
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.

Authors:  Flora Affuso; Emiliano Antonio Palmieri; Pasquale Di Conza; Vincenzo Guardasole; Serafino Fazio
Journal:  Int J Cardiol       Date:  2005-11-02       Impact factor: 4.164

4.  Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.

Authors:  S Faruqi; H Fathi; A H Morice
Journal:  Int J Cardiol       Date:  2009-01-27       Impact factor: 4.164

5.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

6.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

7.  Tadalafil therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Bruce H Brundage; Hossein A Ghofrani; Ronald J Oudiz; Gerald Simonneau; Zeenat Safdar; Shelley Shapiro; R James White; Melanie Chan; Anthony Beardsworth; Lyn Frumkin; Robyn J Barst
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

8.  Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

Authors:  Rebecca E Wrishko; Jasper Dingemanse; Albert Yu; Christelle Darstein; Diane L Phillips; Malcolm I Mitchell
Journal:  J Clin Pharmacol       Date:  2008-02-27       Impact factor: 3.126
  8 in total
  2 in total

Review 1.  Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  George F Lasker; Jason H Maley; Edward A Pankey; Philip J Kadowitz
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Authors:  Adam M Henrie; James J Nawarskas; Joe R Anderson
Journal:  Core Evid       Date:  2015-11-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.